Gaush Meditech

Gaush Meditech FCF Margin

The Free Cash Flow Margin of Gaush Meditech (2407.HK) as of Nov 2, 2026 is 8.00 %. In the previous year, Free Cash Flow Margin was 1.86 % — a change of 330.23% (higher).

FCF Margin

8.00 %

YoY

330.23%

Last updated:

Free Cash Flow Margin of Gaush Meditech is 2025 8.00 % . Free Cash Flow Margin of Gaush Meditech was 2024 1.86 % . It decreases by 330.23% higher compared to the previous year.

The Gaush Meditech FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
15.09 CNY
Jan 1, 2020
13.32 CNY
Jan 1, 2021
10.51 CNY
Jan 1, 2022
17.38 CNY
Jan 1, 2023
14.47 CNY
Jan 1, 2024
1.86 CNY
Jan 1, 2025
8.00 CNY
The Gaush Meditech FCF Margin history
YEARFCF MarginYoY
8.00 %+330.23%
1.86 %-87.14%
14.47 %-16.77%
17.38 %+65.38%
10.51 %-21.12%
13.32 %-11.71%
15.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gaush Meditech Stock analysis

What does Gaush Meditech do? Gaush Meditech Ltd. generates revenue through four business segments. The Proprietary Products segment develops and sells surgical equipment, intraocular lenses, and diagnostic and treatment devices for ophthalmic diseases, along with related software and consumables. The Distribution segment distributes branded ophthalmic medical devices and consumables. The Technical Services segment offers after-sales services including warranty, maintenance, and consumables support. The Others segment handles equipment leasing and intellectual property agency services. Products are used in treating conditions like cataracts, glaucoma, and pediatric ophthalmology across various medical specialties. The company's primary customers include hospitals, clinics, and medical institutions specializing in ophthalmology. These institutions purchase proprietary devices, branded consumables, and technical support services. The firm's focus on ophthalmic subspecialties ensures consistent demand for its products and services in the treatment of eye diseases. Revenue streams are diversified across product development, distribution, and post-sale services. The proprietary segment drives innovation with surgical equipment and lenses, while distribution and technical services provide steady income from established medical partners. Equipment leasing and IP services in the Others segment contribute to additional revenue without requiring direct product sales. Gaush Meditech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gaush Meditech stock

Free Cash Flow Margin of Gaush Meditech is 8.00 % in 2025.

Free Cash Flow Margin of Gaush Meditech changed from 1.86 % to 8.00 %, representing a 330.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Gaush Meditech since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Gaush Meditech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Gaush Meditech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Gaush Meditech